PROTEOME SCIENCES CLOSES RESEARCH CONTRACT WITH TAKEDA

28th October 2009

Proteome Sciences plc ("Proteome Sciences") is pleased to announce that Takeda Pharmaceutical Company Limited ("Takeda") has signed a contract to use PS Biomarker Services™ for a preclinical study.

Proteome Sciences has a strong track-record in the discovery / validation of biomarkers and rapid assay development in neurodegenerative and cancer fields and will apply its proprietary isobaric Tandem Mass Tags® in combination with its mass spectrometric workflows for the Takeda contract.

Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:

"PS Biomarker Services is ideally placed to undertake biomarker programmes at clinical/preclinical stages and we are pleased to be working with Takeda on this project".